Christina Tekle
About
Christina Tekle is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Christina Tekle has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 21 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Christina Tekle's work include Multiple Myeloma Research and Treatments (22 papers), Peptidase Inhibition and Analysis (11 papers) and Protein Degradation and Inhibitors (9 papers). Christina Tekle is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Peptidase Inhibition and Analysis (11 papers) and Protein Degradation and Inhibitors (9 papers). Christina Tekle collaborates with scholars based in United States, France and Italy. Christina Tekle's co-authors include Øystein Fodstad, Jahn M. Nesland, Gunhild M. Mælandsmo, Kirsten Sandvig, Tore‐Geir Iversen, Bo van Deurs, Caroline E. Nunes‐Xavier, Kjersti Flatmark, Marit Kveine Nygren and Karine Flem‐Karlsen and has published in prestigious journals such as Nano Letters, Blood and Scientific Reports.
In The Last Decade
Christina Tekle
30 papers receiving 1.1k citations
Peers
Christina Tekle
Clifford J. Whatcott United States
Eveline Trachsel Switzerland
Camilla L. Christensen Denmark
Bertha Brodin Sweden
Gabriel J. Villares United States
Luigi Portella Italy
Shuji Kitahara Japan
Varvara Petrova Italy
Sylvie Rusakiewicz France
Helen Kalirai United Kingdom
Citations per year, relative to Christina Tekle Christina Tekle (= 1×)
peers
Clifford J. Whatcott
Countries citing papers authored by Christina Tekle
Since
Specialization
Citations
This map shows the geographic impact of Christina Tekle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina Tekle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina Tekle more than expected).
Fields of papers citing papers by Christina Tekle
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Christina Tekle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina Tekle. The network helps show where Christina Tekle may publish in the future.
Co-authorship network of co-authors of Christina Tekle
This figure shows the co-authorship network connecting the top 25 collaborators of Christina Tekle. A scholar is included among the top collaborators of Christina Tekle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina Tekle. Christina Tekle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ocio, Enrique M., Aurore Perrot, Jesús F. San Miguel, et al.. (2025). Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients. Blood. 146(Supplement 1). 2267–2267.
2.
Manier, Salomon, Meletios Α. Dimopoulos, Philippe Moreau, et al.. (2025). Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplantineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial. Haematologica. 110(9). 2139–2150.
3.
Gaballa, Mahmoud, Nobuhiro Tsukada, Kazuhito Suzuki, et al.. (2024). Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis. Blood. 144(Supplement 1). 2411.5–2411.5.
4.
Manier, Salomon, Meletios Α. Dimopoulos, Xavier Leleu, et al.. (2024). P-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ. Clinical Lymphoma Myeloma & Leukemia. 24. S290–S291.
5.
Richardson, Paul G., Aurore Perrot, Joseph Mıkhael, et al.. (2024). Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. Blood Cancer Journal. 14(1). 209–209.
6.
Orlowski, Robert Z., Meletios Α. Dimopoulos, Xavier Leleu, et al.. (2024). Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study. Blood. 144(Supplement 1). 770–770.
7.
Façon, Thierry, Philippe Moreau, Ross Baker, et al.. (2023). Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis. Haematologica. 109(2). 604–616.
8.
Perrot, Aurore, Paul G. Richardson, Joseph Mıkhael, et al.. (2023). P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES. HemaSphere. 7(S3). e3398301–e3398301.
9.
Leleu, Xavier, Jean Fontan, Aurore Perrot, et al.. (2023). Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population. Blood. 142(Supplement 1). 7419–7419.
10.
Leleu, Xavier, et al.. (2022). POSC34 Comparative Efficacy and Safety of Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Using a Matching-Adjusted Indirect Comparison. Value in Health. 25(1). S39–S39.
11.
Martin, Thomas G., Marcelo Capra, Mohamad Mohty, et al.. (2022). Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. Transplantation and Cellular Therapy. 29(2). 134.e1–134.e7.
12.
Martin, Thomas G., Marcelo Capra, Mohamad Mohty, et al.. (2021). Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S65–S65.
13.
Flem‐Karlsen, Karine, Christina Tekle, Tove Øyjord, et al.. (2019). p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Scientific Reports. 9(1). 5839–5839.
14.
Nygren, Marit Kveine, Christina Tekle, Rami Mäkelä, et al.. (2014). Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. British Journal of Cancer. 110(8). 2072–2080.
15.
Boye, Kjetil, et al.. (2012). B7‐H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancer. International Journal of Cancer. 131(11). 2528–2536.
16.
Tekle, Christina, Alexandr Kristian, Yuhua Zhao, et al.. (2011). B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation. Molecular Cancer Therapeutics. 10(6). 960–971.
17.
Giovannetti, Elisa, Richard J. Honeywell, Axel R. Hanauske, et al.. (2009). Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC). Current Drug Targets. 11(1). 12–28.
18.
Tekle, Christina, et al.. (2008). The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion. Current Cancer Drug Targets. 8(5). 404–413.
19.
Giovannetti, Elisa, Clara Lemos, Christina Tekle, et al.. (2008). Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells. Molecular Pharmacology. 73(4). 1290–1300.
20.
Tekle, Christina, Elisa Giovannetti, J. Sigmond, et al.. (2008). Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. British Journal of Cancer. 99(5). 750–759.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Clifford J. Whatcott Breakdown of academic impact, for papers by Eveline Trachsel Breakdown of academic impact, for papers by Camilla L. Christensen Breakdown of academic impact, for papers by Bertha Brodin Breakdown of academic impact, for papers by Gabriel J. Villares Breakdown of academic impact, for papers by Luigi Portella Breakdown of academic impact, for papers by Shuji Kitahara Breakdown of academic impact, for papers by Varvara Petrova Breakdown of academic impact, for papers by Sylvie Rusakiewicz Breakdown of academic impact, for papers by Helen Kalirai